Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Benzinga_recent_news03-10

Here’s what investors need to know. The FDA had previously issued a Complete Response Letter in July 2025, but Capricor said the agency has now lifted that decision following the company's submission ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment